Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Jul 02, 2022 8:55am
187 Views
Post# 34797228

RE:RE:RE:RE:Pretty disappointing if you ask me.

RE:RE:RE:RE:Pretty disappointing if you ask me.I agree this is how it typically works on the venture. We have seen in past the aftermath with pre and post reactions in share volumes.

However, this is Abbvie, a dead serious public entity, now in the big leagues tickle, and everyone is being told information is kept in a vault, with zero tolerance for these antics, and that confidentiality is absolutely paramaount until at least such time the regulations kick in and disclosure reporting prevails. Abbvie would think nothing of severe consequence here, so on one hand it doesn't benefit our collective need to see this excitement happen, on the other hand, its a relief to see that with respect to working with them, everyone has to be on their best behaviour.

So I guess we wait, and in this case, marketing, business relations, process and practices, reporting etc all follow the lead of this larger company. They bring us up in many aspects, and it will always be on their terms. 
<< Previous
Bullboard Posts
Next >>